Quantitative PSA mRNA determination in blood: A biochemical tool for scoring localized prostate cancer

Clinical Biochemistry

Volumn 39, Issue 4, 2006, Pages 333-338

  Zambon, Carlo Federico ^a   Basso, Daniela ^b   Prayer Galetti, Tommaso ^a   Navaglia, Filippo ^b   Fasolo, Michela ^b   Fogar, Paola ^a   Greco, Eliana ^b   Pagano, Francesco ^a   Plebani, Mario ^b  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY HOSPITAL OF PADOVA   (Italy)

Author keywords

Peripheral blood cancer cells; Prostate cancer; PSA mRNA; Quantitative RT PCR

Indexed keywords

MESSENGER RNA; PROSTATE SPECIFIC ANTIGEN;

ADULT; ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; GENE AMPLIFICATION; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CARCINOMA; QUANTITATIVE ANALYSIS;

BASE SEQUENCE; CASE-CONTROL STUDIES; DNA PRIMERS; HUMANS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RNA, MESSENGER; SENSITIVITY AND SPECIFICITY;

EID: 33646078104     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2006.02.001     Document Type: Article

References (30)

1. Greenlee R.T., Hill-Harmon M.B., Murray T., and Thun M. Cancer statistics. CA Cancer J. Clin. 51 (2001) 15-36
2. Hernandez J., and Thompson I.M. Diagnosis and treatment of prostate cancer. Med. Clin. N. Am. 88 (2004) 267-279
3. Mettlin C.J., and Murphy G.P. Why is the prostate cancer death rate declining in the United States?. Cancer 82 (1998) 249-251
4. Wilson S.S., and Crawford E.D. Screening for prostate cancer: current recommendations. Urol. Clin. North Am. 31 (2004) 219-226
5. Lerner S.P., Seale-Hawkins C., Carlton Jr. C.E., and Scardino P.T. The risk of dying of prostate cancer in patients with clinically localized disease. J. Urol. 146 (1991) 1040-1045
6. Prostate Cancer Trialists' Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet 355 (2000) 1491-1498
7. Pantel K., Cote R.J., and Fodstad Ø. Detection and clinical importance of micrometastatic disease. J. Natl. Cancer Inst. 91 (1999) 1113-1123
8. Ghossein R.A., and Bhattacharya S. Molecular detection and characterization of circulating tumour cells and micrometastases in solid tumours. Eur. J. Cancer 36 (2000) 1681-1694
9. Zippelius A., and Pantel K. RT-PCR-based detection of occult disseminated tumour cells in peripheral blood and bone marrow of patients with solid tumours. Ann. N. Y. Acad. Sci. 906 (2000) 110-123
10. Ghossein R.A., and Bhattacharya S. Molecular detection and characterization of circulating tumour cells and micrometastases in prostatic, urothelial, and renal cell carcinomas. Sem. Surg. Oncol. 20 (2001) 304-311
11. Israeli R.S., Miller W.H., Su S.L., et al. Sensitive detection of prostatic hematogenous tumour cell dissemination using prostate specific antigen and prostate specific membrane-derived primers in the polymerase chain reaction. J. Urol. 153 (1995) 573-577
12. Olsson C.A., de Vries G.M., Raffo A.J., et al. Preoperative reverse transcriptase polymerase chain reaction for prostate specific antigen predicts treatment failure following radical prostatectomy. J. Urol. 155 (1996) 1557-1562
13. Ellis W.J., Vessella R.L., Corey E., et al. The value of a reverse transcriptase polymerase chain reaction assay in preoperative staging and follow up of patients with prostate cancer. J. Urol. 159 (1998) 1134-1138
14. Gala J.-L., Heusterspreute M., Loric S., et al. Expression of prostate-specific antigen and prostate-specific membrane antigen transcripts in blood cells: implications for the detection of hematogenous prostate cells and standardization. Clin. Chem. 44 (1998) 472-1781
15. Basso D., Fogar P., Piva M.G., et al. Total PSA, free PSA/total PSA ratio, and molecular PSA detection in prostate cancer: which is clinically effective and when?. Urology 55 (2000) 710-715
16. McIntyre I.G., Clarke R.B., Anderson E., Clarke N.W., and George N.J. Molecular prediction of progression in patients with conservatively managed prostate cancer. Urology 58 (2001) 762-766
17. Hara N., Kasahara T., Kawasaki T., et al. Reverse transcription-polymerase chain reaction detection of prostate-specific antigen, prostate-specific membrane antigen, and prostate stem cell antigen in one millilitre of peripheral blood: value for the staging of prostate cancer. Clin. Cancer Res. 8 (2002) 1794-1799
18. Gao C.-L., Rawal S.K., Sun L., et al. Diagnostic potential of prostate-specific antigen expressing epithelial cells in blood of prostate cancer patients. Clin. Cancer Res. 9 (2003) 2545-2550
19. Martínez-Piñeiro L., Rios E., Martínez-Gomariz M., et al. Molecular staging of prostatic cancer with RT-PCR assay for prostate-specific antigen in peripheral blood and lymph nodes: comparison with standard histological staging and immunohistochemical assessment of occult regional lymph node metastases. Eur. Urol. 43 (2003) 342-350
20. Shariat S.F., Kattan M.W., Erdamar S., et al. Detection of clinically significant, occult prostate cancer metastases in lymph nodes using a splice variant-specific RT-PCR assay for human glandular kallikrein. J. Clin. Oncol. 21 (2003) 1223-1231
21. Cardillo M.R., Di Silverio F., and Gentile V. Reliability of PSA circulating cells as markers of metastatic prostate cancer. Scand. J. Clin. Lab. Invest. 64 (2004) 687-690
22. Straub B., Müller M., Krause H., et al. Detection of prostate-specific antigen RNA before and after radical retropubic prostatectomy and transurethral resection of the prostate using "Light-cycler"-based quantitative real-time polymerase chain reaction. Urology 58 (2001) 815-820
23. Ylikoski A., Pettersson K., Nurmi J., et al. Simultaneous quantification of prostate-specific antigen and human glandular kallikrein 2 mRNA in blood samples from patients with prostate cancer and benign disease. Clin. Chem. 8 (2002) 1265-1271
24. Gelmini S., Tricarico C., Petrone L., et al. Real-time RT-PCR for the measurement of prostate-specific antigen mRNA expression in benign hyperplasia and adenocarcinoma of prostate. Clin. Chem. Lab. Med. 41 (2003) 261-265
25. Kurek R., Ylikoski A., and Renneberg H. Quantitative PSA RT-PCR for preoperative staging of prostate cancer. Prostate 56 (2003) 263-269
26. Straub B., Müller M., Krause H., Schrader M., and Miller K. Quantitative real-time RT-PCR for detection of circulating prostate-specific antigen mRNA using sequence-specific oligonucleotide hybridisation probes in prostate cancer patients. Oncology 65 Suppl. 1 (2003) 12-17
27. Henke W., Jung M., and Jung K. Increased analytical sensitivity of RT-PCR of PSA mRNA decreases diagnostic specificity of detection of prostatic cells in blood. Int J Cancer 70 (1997) 52-56
28. Lintula S., and Stenman U.-H. The expression of prostate-specific membrane antigen in peripheral blood leukocytes. J Urol 157 (1997) 1969-1972
29. Lintula S., Vesalainen S., and Rannikko A. Quantification of prostate specific antigen mRNA levels in circulation after prostatic surgery and endocrine treatment by quantitative reverse transcription-polymerase chain reaction. Scand. J. Clin. Lab. Invest. 64 (2004) 93-100
30. Marzo DeA.M., Nelson W.G., Isaacs W.B., and Epstein J.I. Pathological and molecular aspects of prostate cancer. Lancet 361 (2003) 955-964